{"id":"https://openalex.org/W4237178682","doi":"https://doi.org/10.1182/blood.v122.21.2663.2663","title":"Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)","display_name":"Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W4237178682","doi":"https://doi.org/10.1182/blood.v122.21.2663.2663"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.2663.2663","doi":"https://doi.org/10.1182/blood.v122.21.2663.2663","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.2663.2663","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049385583","display_name":"Elias Joseph Jabbour","orcid":"https://orcid.org/0000-0003-4465-6119","observed_orcids":["https://orcid.org/0000-0003-4465-6119"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elias Jabbour","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109030239","display_name":"Hagop Kantarjian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038307470","display_name":"Deborah Ann Thomas","orcid":"https://orcid.org/0000-0002-2656-343X","observed_orcids":["https://orcid.org/0000-0002-2656-343X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah A. Thomas","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000750846","display_name":"Farhad Ravandi","orcid":"https://orcid.org/0000-0002-7621-377X","observed_orcids":["https://orcid.org/0000-0002-7621-377X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Ravandi","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge E. Cortes","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046097970","display_name":"Stefan H Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan H. Faderl","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088307376","display_name":"Naveen Pemmaraju","orcid":"https://orcid.org/0000-0002-1670-6513","observed_orcids":["https://orcid.org/0000-0002-1670-6513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naveen Pemmaraju","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020340537","display_name":"Tapan Mahendra Kadia","orcid":"https://orcid.org/0000-0002-9892-9832","observed_orcids":["https://orcid.org/0000-0002-9892-9832"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tapan M. Kadia","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043585566","display_name":"Rebecca E. Garris","orcid":"https://orcid.org/0000-0001-8009-5529","observed_orcids":["https://orcid.org/0000-0001-8009-5529"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Garris","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109414891","display_name":"Hillary Prescott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prescott Hillary","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055045706","display_name":"Gautam M. Borthakur","orcid":"https://orcid.org/0000-0001-7679-6453","observed_orcids":["https://orcid.org/0000-0001-7679-6453"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gautam Borthakur","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O'Brien","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"122","issue":"21","first_page":"2663","last_page":"2663"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9047999978065491,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9047999978065491,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.08309999853372574,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","score":0.9750000238418579},{"id":"https://openalex.org/keywords/hyper-cvad","display_name":"hyper-CVAD","score":0.8339999914169312},{"id":"https://openalex.org/keywords/ponatinib","display_name":"ponatinib","score":0.9779999852180481},{"id":"https://openalex.org/keywords/bcr-abl-tyrosine-kinase-inhibitors","display_name":"BCR-ABL tyrosine kinase inhibitors","score":0.7390000224113464},{"id":"https://openalex.org/keywords/t315i-mutation","display_name":"T315I mutation","score":0.8209999799728394},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5569999814033508},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.722000002861023},{"id":"https://openalex.org/keywords/complete-cytogenetic-response","display_name":"complete cytogenetic response","score":0.8980000019073486},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.5789999961853027},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.6800000071525574},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.5690000057220459},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8379999995231628},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.3269999921321869},{"id":"https://openalex.org/keywords/central-nervous-system-diseases","display_name":"central nervous system disorders","score":0.4410000145435333},{"id":"https://openalex.org/keywords/cytogenetic-monitoring","display_name":"cytogenetic monitoring","score":0.382999986410141}],"concepts":[{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.9237676858901978},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7858660221099854},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.6994775533676147},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.6067021489143372},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5822693109512329},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.5080718994140625},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.44284945726394653},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.42022591829299927},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.41995179653167725},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38291025161743164},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.3221745491027832},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.18060573935508728}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.2663.2663","doi":"https://doi.org/10.1182/blood.v122.21.2663.2663","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.2663.2663","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2591848289","https://openalex.org/W2891733953","https://openalex.org/W4310107855","https://openalex.org/W2508045402","https://openalex.org/W2197145501","https://openalex.org/W3216874257","https://openalex.org/W2986868459","https://openalex.org/W2754648787","https://openalex.org/W1838408716","https://openalex.org/W4310117813"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Combination":[2],"of":[3,15,34,43,80,94,96,123,155,224,244,248,301,341,357,387,398,403,421,455,485,492,531,607,703],"cytotoxic":[4],"chemotherapy":[5,81,225,364],"with":[6,38,74,87,104,115,132,175,184,211,221,306,483,609,622],"imatinib":[7,105,524],"or":[8,106,523,705],"dasatinib":[9,521],"is":[10,19,62,412,611],"effective":[11,615],"in":[12,36,53,66,72,173,180,232,238,255,280,295,360,414,457,463,477,489,497,502,540,545,616,620],"the":[13,28,151,161,169,302,355,490],"treatment":[14,404],"Ph+":[16,39,54,118,213,307,623],"ALL.":[17,40,624],"Ponatinib":[18,142],"a":[20,31,75,242,320,327,344,351,385,393,396,419,527],"more":[21],"potent":[22],"BCR-ABL":[23],"inhibitor.":[24],"It":[25],"also":[26],"suppresses":[27],"T315I":[29,76],"clones,":[30],"common":[32],"cause":[33],"relapse":[35],"pts":[37,114,174,210,217,251,282,293,304,381,417,459,506,517,536,584,621],"Clinical":[41],"trials":[42],"ponatinib":[44,83,185,200,610],"have":[45,240,383,391,585],"demonstrated":[46],"its":[47],"high":[48,133],"activity":[49],"and":[50,71,82,91,137,190,192,215,234,332,365,372,376,429,437,440,442,470,487,500,515,539,557,571,595,601,613],"limited":[51],"toxicity":[52,452],"leukemias.":[55],"The":[56,78,592,605],"complete":[57],"cytogenetic":[58,315,329,336],"response":[59,89,330],"(CCyR)":[60],"rate":[61],"40%":[63],"to":[64,427,512,520],"50%":[65],"patients":[67],"failing":[68],"2-3":[69],"TKIs":[70],"those":[73,102],"mutation.":[77],"combinations":[79],"may":[84],"be":[85],"associated":[86],"better":[88],"rates":[90,598],"higher":[92],"likelihood":[93],"eradication":[95],"minimal":[97],"residual":[98],"disease":[99,289],"(MRD)":[100],"than":[101],"reported":[103,278],"dasatinib.":[107],"Methods":[108],"In":[109],"this":[110],"phase":[111],"II":[112],"trial,":[113],"newly":[116],"diagnosed":[117],"ALL":[119,214],"received":[120,182,241],"8":[121],"cycles":[122,172,246],"hyper-CVAD":[124],"(fractionated":[125],"cyclophosphamide,":[126],"vincristine":[127,191],"[VCR],":[128],"doxorubicin,":[129],"dexamethasone)":[130],"alternating":[131],"dose":[134,510],"methotrexate":[135],"(MTX)":[136],"cytarabine":[138],"every":[139],"21":[140,535],"days.":[141],"was":[143,166,204,229,259,267,277,435],"given":[144],"at":[145,265,290,317,338,354,395,418],"45":[146,186],"mg":[147,187,514],"po":[148,188],"daily":[149,189],"for":[150,160,195,432,445],"first":[152,170],"14":[153],"days":[154,444],"cycle":[156,223,298,347,433,580],"1":[157,235,323,325,434,466,480,482,488,542,561,572],"then":[158],"continuously":[159],"subsequent":[162,446],"7":[163,532],"cycles.":[164],"Rituximab":[165],"administered":[167],"during":[168],"4":[171,349],"CD20":[176,275],"expression":[177,276],"\u226520%.":[178],"Pts":[179],"CR":[181,296,546],"maintenance":[183,254],"prednisone":[193],"monthly":[194],"2":[196,216,284,471,503,516,581],"years":[197,261],"followed":[198],"by":[199,314,368,374,409],"indefinitely.":[201],"MRD":[202,407],"monitoring":[203],"conducted.":[205],"Results":[206],"To":[207,378],"date":[208],"28":[209],"untreated":[212],"previously":[218],"treated":[219],"(1":[220],"prior":[222],"before":[226],"Ph+/BCR-ABL":[227],"status":[228],"known":[230],"not":[231],"CR,":[233,339],"post":[236,362,568,579],"HCVAD-dasatinib":[237],"CR)":[239],"median":[243,397,420,528],"6":[245,583],"(1-8)":[247],"therapy;":[249],"10":[250,399],"are":[252,537],"receiving":[253],"CR.":[256],"Median":[257,263,425],"age":[258],"55":[260],"(28\u201375).":[262],"WBC":[264],"diagnosis":[266],"3.55":[268],"x":[269,273],"109/L":[270],"(1.6":[271],"-629":[272],"109/L).":[274],"positive":[279,373],"11":[281,458,505],"(37%).":[283],"(7%)":[285],"had":[286,326,334,350,508],"concomitant":[287],"CNS":[288],"diagnosis.":[291],"All":[292],"were":[294,599],"after":[297,322,346,552],"1.":[299],"24":[300],"26":[303,380,415],"(92%)":[305],"metaphases":[308,312],"(at":[309],"least":[310],"20":[311],"analyzed)":[313],"analysis":[316,337],"baseline":[318],"achieved":[319,343,384,392],"CCyR":[321,345,361],"cycle;":[324],"minor":[328],"only":[331],"one":[333],"no":[335],"both":[340],"them":[342],"2;":[348],"diploid":[352,367],"karyotype":[353],"start":[356],"therapy":[358,556],"(one":[359],"previous":[363],"3":[366,422,451,464,478,498],"standard":[369],"G-banding":[370],"technique":[371],"FISH":[375],"PCR).":[377],"date,":[379],"(93%)":[382],"MMR,":[386],"whom":[388],"19":[389],"(70%)":[390],"CMR":[394],"weeks":[400,423],"from":[401,547,564,573],"initiation":[402],"(2":[405],"-28).":[406],"assessment":[408],"flow":[410],"cytometry":[411],"negative":[413],"(90%)":[416],"(3-14).":[424],"time":[426],"neutrophil":[428],"platelet":[430],"recovery":[431],"18":[436],"23":[438],"days,":[439],"16":[441],"22":[443],"cycles,":[447],"respectively.":[448,603],"Grade":[449],"\u2265":[450],"included":[453],"increase":[454],"LFT\u2019s":[456],"(37%),":[460],"thrombotic":[461],"events":[462],"(10%,":[465,479],"renal":[467],"vein":[468],"thrombosis":[469],"pulmonary":[472],"emboli),":[473],"myocardial":[474],"infarction":[475],"(MI)":[476],"unexplained,":[481],"history":[484],"cardiomyopathy,":[486],"context":[491],"sepsis":[493,569],"),":[494],"skin":[495],"rash":[496],"(15%),":[499],"pancreatitis":[501],"(7%).":[504],"(37%)":[507],"their":[509],"reduced":[511],"30":[513],"(10%)":[518],"switched":[519],"(n=1)":[522],"(n=1).":[525],"With":[526],"follow":[529],"up":[530],"months":[533],"(1-20),":[534],"alive":[538],"CR;":[541],"pt":[543,562],"died":[544,563],"an":[548,587,700],"unrelated":[549],"cardiac":[550],"event":[551],"being":[553],"taken":[554],"off":[555],"placed":[558],"on":[559,699],"imatinib,":[560],"multiple":[565],"organ":[566],"failure":[567],"(C2D13),":[570],"non":[574],"ST":[575],"elevation":[576],"MI":[577],"(NSTEMI)":[578],"(C2D41).":[582],"undergone":[586],"allogeneic":[588],"stem":[589],"cell":[590],"transplant.":[591],"1-year":[593],"progression-free":[594],"overall":[596],"survival":[597],"100%":[600],"88%":[602],"Conclusion":[604],"combination":[606],"hyperCVAD":[608],"safe":[612],"highly":[614],"achieving":[617],"molecular":[618],"remissions":[619],"Disclosures:":[625],"Jabbour:":[626],"Ariad:":[627],"Consultancy;":[628,630,632],"Novartis:":[629,644,691],"BMS:":[631,694],"Pfizer:":[633,657,683],"Consultancy.":[634],"Ravandi:Sunesis:":[635],"Consultancy,":[636,655,663,673,677,680,684,688],"Honoraria,":[637,641,645,651],"Research":[638,642,646,652,660,667,670,681,685,689,692,695,708],"Funding;":[639,643,647,653,661,668,671,682,686,690,693],"Celgene:":[640],"Bristol":[648],"Myers":[649],"Squibb:":[650],"Teva:":[654,687],"Honoraria;":[656,658,664,674],"Merck:":[659],"Bayer/Onyx:":[662],"EMD":[665],"Serono:":[666],"Medimmune:":[669],"Amgen:":[672],"Seattle":[675],"Genetics:":[676],"Honoraria.":[678],"Cortes:Ariad:":[679],"Funding.":[696,709],"Faderl:Sanofi-Aventis:":[697],"Membership":[698],"entity\u2019s":[701],"Board":[702],"Directors":[704],"advisory":[706],"committees,":[707]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-12T00:00:00"}